Summary of Radiopharm Theranostics Conference Call Company Overview - Company Name: Radiopharm Theranostics - Ticker Symbols: ASX (Australia), NASDAQ: RADX - Founded: 2021 in Australia - Core Business: Radiopharmaceutical imaging and therapies - Management Team: Primarily U.S.-based, located on the East Coast - Public Listing: Dual-listed on ASX and NASDAQ since December 2024 [2][4] Key Business Strategies - Differentiation: Focus on unique mechanisms of action in radiopharmaceuticals, avoiding common targets like PSMA, SSTR2, and FAP [3] - Clinical Development: Four therapeutic molecules and one imaging molecule currently in clinical stages [2][5] - Supply Chain: Established a secure and redundant supply chain, with strategic partnerships [4] Strategic Partnerships - Lantheus: Co-development agreement and largest shareholder (12% stake) [4] - MD Anderson Cancer Center: Joint venture for developing new radiopharmaceuticals [4][21] Product Pipeline - RAD101: Imaging agent for brain metastasis, currently in Phase IIB trials with 12 out of 30 patients enrolled. Expected completion by Q1 2026 [5][6][10] - RAD204: Therapeutic targeting PD-L1, in dose escalation trials, with promising early results [6][15] - RAD202: Therapeutic targeting HER2, also in dose escalation trials, showing significant tumor uptake [18][19] - B7-H3: Emerging mechanism for multiple solid tumors, IND approval received, expected to start Phase I soon [8][9] - KLK3: Prostate cancer drug using Tb-161 isotope, expected to start Phase I soon [9] Market Potential - RAD101 Market Assessment: Estimated total addressable market of $500 million to $700 million in the U.S. alone, with a projected market share of 94% due to lack of competition in brain metastasis imaging [26][27] - Patient Population: 300,000 new patients diagnosed annually with brain metastasis [10] Financials and Capital Raise - Recent Capital Raise: Conducted to extend cash runway into Q1 2027, following a previous raise in June 2024 [5][20] - Cash Position: Current cash runway is eight months, prompting the recent capital raise [20][27] Clinical Trial Updates - RAD101: Primary endpoint focuses on concordance with MRI, with secondary endpoints assessing additional lesion detection [23] - RAD204 and RAD202: Expected readouts in mid-2026 and end of 2026, respectively [25] Conclusion - Outlook: Positive early signals from clinical trials, with a strong focus on expanding the use of radiopharmaceuticals in oncology [25]
Radiopharm Theranostics (NasdaqCM:RADX) 2025 Conference Transcript